Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension

ConclusionsIT administration of rituximab via a ventricular catheter was well tolerated. Considering the meningitis cases, the risk of infection was not negligible. The continued loss of walking speed indicates that IT rituximab was not able to stop disease progression.Classification of evidenceThis study provides class IV evidence that intraventricularly administered rituximab in progressive MS is associated with a risk for bacterial meningitis and does not halt disease progression.EU Clinical Trial RegisterEudraCT; 2008-002626-11 and 2012-000721-53
Source: Journal of Neurology - Category: Neurology Source Type: research